Researchers from Yale Cancer Center have found that PARP Inhibitors might offer an effective treatment paradigm for two rare inherited cancers, Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) and Succinate Dehydrogenase-related Hereditary Paraganglioma and Pheochromocytoma (SDH PGL/PCC).